Vivani Medical Announces Private Placement Equity Financing
Vivani Medical (NASDAQ:VANI) Jumps on Positive SLIM-1 Phase 1 Data Despite Pre-Revenue Q3
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
Vivani Medical: Q3 Earnings Snapshot
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
Vivani Medical Q3 EPS $(0.08), Inline
Vivani Medical Announces Participation in Upcoming Investor Conferences
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani strikes reverse-merger agreement with ClearOne for BCI business
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139
Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.